Tal Healthcare’s Post

The last 3 weeks have been incredible for the Elixir Associates team in terms of Clinical placements. 🙌🎈 We have successfully helped our clients with the following requirements: ➖ Vice President, Clinical Development - Autoimmune ✅ ➖ Senior Director, Clinical Operations - Oncology ✅ ➖ Director, Clinical Operations - Oncology ✅ ➖ Associate Director, Clinical Operations - Oncology ✅ ➖ Clinical Trial Manager - Oncology ✅ ➖ Clinical Research Associate - Obesity ➖ Senior Clinical Trial Associate - Obesity ✅ Great work by Connor Harknett, Jake Couldrick, Thomas Vos, Dan Spencer, Nahum Wood & Carlos Biggemann to build these Clinical teams across California & Massachusetts !!! #ThankYou ✊🔵🟡 #Elixir #Hiring #Biotech #Pharma #Oncology #Hematology #CellTherapy #CNS #Cardiovascular #RareDisease #InfectiousDisease #MedicalAffairs #LifeSciences #QualityAssurnace #Biometrics #Regulatory #Talent #ClinicalOperations #ClinicalDevelopment #Recruiting #ClinicalScience

  Presenting at the European Hematology Association -Patient Joint Symposium at #EHA2024 in Madrid was a great experience. The session, “Fair Pricing: Does the #Value of New Medicines in #Hematology Justify the High Prices?” attracted many attendees, highlighting a critical issue in hematology. Patients with hematological diseases face significant challenges in accessing life-saving treatments due to prolonged price negotiations and lack of reimbursement from insurance companies and governments. These hurdles often deter companies from seeking reimbursement in certain countries, leaving patients without vital medications. This issue affects all European countries, regardless of income level. For example, effective treatments for multiple myeloma, #CAR-T cell therapy, and #gene therapy for #hemophilia B come with staggering costs of €420,000 and €2.8 million, respectively. Treatments for paroxysmal nocturnal hemoglobinuria (#PNH), a non-malignant, ultra-rare, life-threatening disease, such as Eculizumab, Ravulizumab, and Pegcetacoplan, have also improved patient outcomes but have annual prices per patient ranging from £245,700 to £324,110. These high costs underscore the need for a sustainable pricing model, as they displace other essential healthcare services. Critical questions arise: How can we address these high prices? How can we improve affordable access to treatments that add significant value to patients? The ASCERTAIN project suggests several key factors for fair pricing in pharmaceuticals: -Costs of Drug Development: Including R&D, production, marketing, distribution, and public investments. - Affordability: Ensuring affordability for health systems and patients, considering countries' ability to pay. - Value: Assessing therapeutic value, alternative prices, and societal willingness-to-pay. - Incentives for Innovation: Ensuring manufacturers are rewarded to incentivize future innovations while maintaining long-term product availability. All panelists agree that addressing these issues is crucial for improving access to essential treatments and ensuring innovations benefit patients worldwide. Pharmaceutical companies acknowledge that improving access involves key strategies: innovative pricing, aligning research and development (R&D) with healthcare needs, and strengthening healthcare systems. These approaches help address the needs of those currently lacking essential treatments.   #hematology #access #prices #innovation #value   Frank Leebeek Maria Piggin Maximilian Salcher-Konrad Manoela Manova Christian Schlossmacher

Introduction to Classical Hematology - New Post Alert! 😀 What is classical hematology? its role in healthcare, career development, mentorship, and career opportunities. An exciting and evolving field!

Exciting news for healthcare innovation! 🌟 Washington University joins forces with Deerfield Management to launch VeritaScience, a cutting-edge R&D venture designed to transform scientific discoveries into life-saving therapies. With Deerfield's $130M backing over a decade, this initiative promises to accelerate drug development in critical areas like oncology, neurology, and more. Get the full scoop on how this academia-industry powerhouse will streamline the journey from lab to patient care. #VeritaScience #HealthcareInnovation #PartnershipPower #TherapeuticsDevelopment #WashingtonUniversity #DeerfieldManagement 🧬💊🔬

Animation by MadMicrobe Studios on the therapeutic effects of SIMBA drug therapy on chemotherapy-induced neutropenia. Explore more work by MadMicrobe on the Medical Illustration & Animation Sourcebook online site: https://buff.ly/32rPRE2 #neutropenia #chemotherapy #therapy #treatment #oncology #pharmacology #medical #animation #medicalanimation #medicalanimators #3D #biology #molecularbiology

"Thrilled to announce that I've clinched first prize at the Uttar Pradesh Hematology Group Conference, hosted by KGMU's Department of Clinical Hematology! My oral presentation on 'Von Willebrand disease' garnered recognition and applause from esteemed peers in the field. Grateful for the opportunity to share insights and contribute to advancing knowledge in hematology. Looking forward to more fruitful collaborations and discoveries ahead! #Hematology #VonWillebrandDisease #ResearchExcellence"

Exciting advancements in oncohematology:

Wilms Tumor Market Size, Share & Trends Analysis Report By Treatment Type (Surgery, Chemotherapy, Radiation therapy) By End User (Hospitals, Cancer Centers, Surgical Centers, Ambulatory Surgical Center), Global Economy Insights, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2023 - 2031. 𝐈𝐌𝐈𝐑 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 #Note: The above outline provides a general structure for the content. You may modify and expand it based on the specific requirements and available information.   📚𝐆𝐞𝐭 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐀𝐭 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐏𝐫𝐢𝐜𝐞:📝👇 https://lnkd.in/duCEKrvk   📚𝐑𝐞𝐩𝐨𝐫𝐭 𝐅𝐨𝐜𝐮𝐬𝐞𝐝 𝐎𝐧 𝐓𝐨𝐩 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬:👇 Apotex Inc. Bayer HealthCare Diabetes Care Bear Necessities Pediatric Cancer Foundation Bristol Myers Squibb Roche Medilexicon Healthcare India Limited, Jaipur Merck Group Sanofi Pasteur MSD SELLAS Life Sciences Group, Inc. The Pablove Foundation

Contribute to Patient Care: Submit Your Hematology Research Url: https://lnkd.in/gDgE_iAF #CancerTreatment #Hematopoiesis #TumorBiology #PrecisionOncology #HematologicDiseases #HematologyOncology #HematologyJournal #OncologyJournal

Laboratory technology is ever evolving—and hematology is no exception. How can lab results help clinicians in their diagnostic decision making? How can AI help? Read “Can labs bridge the hematology data disconnect?” from #CAPTODAY to learn more! https://bit.ly/3Ys3zCj #Hematology #Diagnostics #DigitalHematology